Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Li J
  NCT04892459		 RCTCanSino (Convidecia)CoronaVac (SinoVac)COVID-19 prophylaxis (excluding children)NA
147/152 inconclusive
    No thromboses, vaccine-related anaphylaxis or other serious adverse events were observed in any of the groups by day 28 after the booster
    Fengcai
          NCT04566770    		 RCTCanSino (Convidecia)placeboCOVID-19 prophylaxis (excluding children)NA
    		320/110 safety concern
    • statistically significant 19.2-fold increase in systemic adverse reaction, any, dose 1
    • statistically significant 3.4-fold increase in systemic adverse reaction, any, dose 2
    CanSino phase 2 (Zhu)
          NCT04341389    		 RCTCanSino (Convidecia)placeboCOVID-19 prophylaxis (excluding children)NA
    		382/126 inconclusive
      No serious adverse events were documented within 28 days

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons